ProBioGen Plans Expansion
ProBioGen, a biopharmaceutical drug manufacturer in Berlin, spends ?20 million to double its workforce.
ProBioGen AG announced that it will be investing €20 million to double its workforce in Berlin. ProBioGen develops novel biotechnological processes for the production of biopharmaceutical drug substances to treat serious diseases. The company specializes in cell line and process development up to GMP contract manufacturing and develops technologies to improve biotechnologically active substances. ProBioGen plans to exploit its internal potential for the development of production cell lines, process engineering, and GMP manufacturing of biopharmaceuticals.
"Together with our parent company, we will continue to expand and invest in Berlin," stated Wieland Wolf, CEO, in a press release. "With an investment of around 20 million euros, we will strengthen our market position, add two additional disposable 1000L bioreactors and, within the next two years, will double our staff from currently 75 highly skilled and dedicated employees."
Source: ProBioGen
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
